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Abstract 
The study of phenotypic and genetic intratumor heterogeneity in glioblastoma is attracting a lot of 
attention. Recent studies have demonstrated that transcriptional profiling analysis can help 
interpret the complexity of this disease. Previously proposed molecular classifiers have been 
recently challenged due to the unexpected degree of intratumor heterogeneity that has been 
described spatially and at single cell level. Different computational methods have been employed 
to analyze this huge amount of data, but new experimental designs including multisampling from 
individual patients and single-cell experiments require new specific approaches. In light of these 
results, there is hope that integration of genetic, phenotypic and transcriptional data coupled with 
functional experiments might help define new therapeutic strategies and classify patients 
according to key pathways and molecular targets that can be further investigated to develop 
personalized and combinatorial treatment strategies.  
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analysis. 
 
Tumor heterogeneity 
Cancer is characterized by heterogeneity that is based on extensive phenotypic and genetic 
diversity between tumors of the same type (Intertumor heterogeneity) as well as among cells 
within the same tumor (intratumor heterogeneity) [1].  
Recently, technological advancements have allowed interrogation of cancer genomes at high 
resolution [2]. Deep genome-wide analyses of mutations and complex computational approaches 
have allowed the reconstruction of the genomic history of tumors [3, 4]. This has revealed that 
tumors of the same histological subtype share only a minority of genetic aberrations thus 
explaining the differential patterns of response to therapies among patients with the same tumor.  
Such complexity is further exacerbated by increasing evidence of genetic diversity among areas of 
the same tumor or between the tumor and its metastases (spatial intratumor heterogeneity) [5-
17], serial sampling taken during tumor evolution and relapse (temporal intratumor 
heterogeneity) [18-25], and single cells of the same tumor [26-31].   
This scenario is even more complicated due to the stochastic and unpredictable behavioral 
diversity of subclones with similar genotypes as well as the presence of aberrations that occur 
through post-translational and epigenetic modifications. The tumor microenvironment (including 
endothelial cells, pericytes, immune inflammatory cells, cancer-activated fibroblasts and stromal 
cells) adds an extra level of heterogeneity which affects tumor growth, progression and obviously 
treatment response [32, 33], thus therapeutic targeting should be aimed at several levels to 
achieve disease eradication.  
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Intratumor heterogeneity in glioblastoma 
Glioblastoma (GBM) is the commonest brain tumor in adults and is characterized by a high 
degree of heterogeneity both at cellular and molecular level [34, 35]. At clinical presentation it can 
be classified either as primary or secondary with the former being characterized by absence of 
clinical or histological evidences of a less malignant tumor and the latter being the result of 
progression from a low-grade glioma [36].  
Historically, primary and secondary GBMs have been considered conceptually different but from a 
clinical and histopathological perspective they remain largely identical [36]. In the last decade, it 
has become increasingly clear that primary and secondary GBMs represent different entities 
characterized by distinct genetic pathways. In this text we refer to primary GBM unless specified 
otherwise; yet, here we summarize the genetic alterations and pathways involved in the 
development of both primary and secondary GBMs as a service to the readers. 
Primary and secondary GBMs show genetic alterations that are significantly different in frequency: 
LOH 10q is frequent in both primary and secondary GBMs, whereas epidermal growth factor 
receptor (EGFR) amplification, p16INK4a deletion and phosphatase and tensin homolog (PTEN) 
mutations are more frequent in primary GBMs. Isocitrate dehydrogenase 1 (IDH1) mutations occur 
in approximately 10% of all GBMs [37] and are enriched in secondary GBMs [38]. p53 mutations 
are early common genetic events in secondary GBMs [36] but are present also in approximately 
30% of primary GBMs. Despite this, more than 70% of primary GBMs show alterations in the p53 
pathway [35] .  
In addition to the amplification of EGFR (present in almost 50% of GBM [39-41]) and the presence 
of extrachromosomal double minutes copies of this gene [42], EGFR amplicons are often mutated 
in several variants. Among these, the most common is a deletion of exon 2-7 which generates a  
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truncated receptor that is unable to bind its ligand and is constitutively active (EGFRvIII) [36]. 
Amplification of EGFR is frequently associated with deletion of the INK4a/Arf gene locus that 
encodes two tumor suppressors, p16INK4a and p19Arf (p14Arf in humans), translated from 
alternatively spliced mRNAs [43]. p16INK4a prevents the formation of the complex between cyclin-
dependent kinase 4 (CDK4) and cyclin D1, thus preventing G1 entry [44], while p19Arf stabilizes p53 
through binding to mouse double minute 2 homolog (MDM2).  
The handling of GBM is challenging due to the heterogeneous nature of the disease, 
invasive potential and poor response to chemo- and radio-therapy. Median life expectancy in 
optimally managed patients is only 17-62 weeks with only 25% surviving 2 years [45]. The current 
clinical management of patients diagnosed with a GBM involves a combination of surgery, 
radiotherapy and chemotherapy. Radiotherapy has been the principal therapeutic modality since 
the late 1970s and the addition of targeted chemotherapy has only provided modest benefit [45, 
46].  
The term ‘multiforme’ that is commonly used to describe GBM clearly summarizes the 
various morphological characteristics of the tissue and of the cell populations showing 
heterogeneous tracts in their phenotype and genotype [47]. Despite extensive brain tumor biology 
studies, the definitive identification of the cell type(s) that contribute to tumor growth has yet to 
come [48]. This is extremely relevant in order to provide insights into the cellular target(s) of the 
initial mutational events and to dissect the phenotypic heterogeneity emerging as a result of 
tumor growth.  
Evidences from the cancer stem cell (CSC) hypothesis suggest that tumors hijack the functional 
properties of somatic stem cells and phenotypic heterogeneity is the result of a hierarchical 
organization of the tumor with its cell population showing various degrees of tumorigenic 
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potential regardless of their genotype and epigenetic status [49]. However, the CSC hypothesis 
does not address the issue of cell of origin [50]. More importantly, the lack of identification of 
cellular targets and the phenotypic complexity of the disease at the time of clinical presentation 
have hampered the development of innovative therapeutic approaches aimed at improving 
patient survival. 
 
Spatial and temporal genetic intratumor heterogeneity in glioblastoma 
The most extensive and well-characterized type of heterogeneity in GBM occurs at the 
genetic level. Initial studies in the 1980s revealed intratumor heterogeneity in GBM tissues and 
cells [51, 52] and were complemented by more sophisticated analyses using comparative genomic 
hybridization and laser scanning cytometry of microdissected GBM tissues [53, 54]. Seminal 
molecular studies in the 1990s shed light on the genetic heterogeneity across all glioma grades 
[55-57] and identified critical alterations in pathways that were mutually exclusive in GBM 
(CDKN2A (p16INK4A, MTS1) and CDK4 versus RB) suggesting genetic heterogeneity among patients 
[58, 59]. 
In the last years, large-screening data have elucidated the role of key signaling pathways in 
GBM by performing comprehensive analysis and integrating genomic, epigenomic and 
transcriptional data  [60-62]. Focal somatic copy-number alterations found in The Cancer Genome 
Atlas (TCGA) study are amplification of EGFR, CDK4, CDK6, PDGFRA, MDM2, MDM4, MET, MYCN, 
CCND2 and PIK2CA. In addition to these well-know aberrations in GBM, less common alterations 
were also detected, such as the amplification of the serine/threonine protein kinase AKT3 and the 
homozygous deletions of NF1 and PARK2 [62]. Mutations were also found in PTEN, TP53, EGFR, 
PIK3CA, PIK3R1, NF1, RB1, IDH1 and PDGFRA [60] and an additional 61 mutated genes were  
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identified at low frequency [60]. 
This scenario was further complicated by the elegant observation that amplifications of the 
receptor tyrosine kinases (RTKs; EGFR, PDGFRA and MET) show a mosaic pattern in distinct 
population of cells coexisting in the same GBMs [10, 13]. In particular, a striking example of RTK 
genetic intratumor heterogeneity is found in studies focusing on the expression of EGFR wild type 
and that of its mutant oncogenic variant vIII [63]: while EGFR over-expression is widespread in the 
majority of GBM, immunostaining for EGFRvIII typically shows that only a minority of the tumor 
cells are positive for this variant. Interestingly, GBM characterized by EGFR overexpression and 
presence of EGFRvIII are likely to show ependymal spread of the disease [64]. The interaction 
between EGFR wild type and vIII as well as the downstream signaling pathway activated by this 
functional cooperation has been described in a study by Fan and colleagues [65] who showed that 
EGFR phosphorylates the mutant variant vIII and causes its nuclear translocation. In the nucleus,  
EGFRvIII forms a nuclear complex with STAT3 and is able to drive transformation [65]. The 
coexpression of EGFR wild type and vIII drives the phosphorylation of STAT in vitro and in vivo and 
enhances tumorigenicity providing further insights into the oncogenic cooperation among variants 
of the same genetic lesion. A more recent study has suggested that an additional mechanism 
involving the activation of MET operates between EGFR wild type and vIII [66]. All multiple somatic 
events and the heterogeneous expression of EGFR and its variants in GBM have been 
comprehensively resolved at single-cell level [67]. Mutations in a single RTK, like EGFR, contribute 
to enhance clonal diversification which further expands upon the recent observation of intratumor 
heterogeneity of multiple concurrent RTK amplifications [10, 13]. 
Most recent studies have revealed spatial and temporal intratumor heterogeneity [5, 8, 
26]. Using a fluorescence-guided resection method based on 5-ALA [68, 69] we have been able to  
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dissect distinct regions of the same GBM, starting from the residual disease (margin) that is left 
behind during surgery [68] to the resected disease (tumor mass) [8]. This has allowed us to 
describe the clonal evolutionary trajectories of GBM development and to show that EGFR 
amplification and CDKN2A/B/p14ARF deletion represent early events whereas PDGFRA 
amplification and PTEN deletion emerge later during GBM evolution. 
An even more interesting observation of spatial intratumor heterogeneity came from the 
histological and genomic analysis of the subependymal zone (SEZ), the most well characterized 
neurogenic region of the human brain. Our recent study revealed that this region contributes to 
the genetic intratumor heterogeneity of GBM and is characterized by patterns of drug response 
that differ from the tumor mass [5]. Phylogenetic reconstruction showed different GBM evolution 
patterns in the analyzed patients where tumor cells from the SEZ correspond to clones that are 
generated early during tumor growth [5], in agreement with what proposed in mouse model 
studies [70-75].  
The use of patient-derived xenografts (PDX) has become increasingly popular in recent years, as 
they are believed to faithfully mimic the original human disease. In GBM, it has been shown that 
the ‘avatar’ model based on PDX recapitulates the pathological and genomic features of the 
original tumor and can be used to identify key regulatory signatures of clinical aggressiveness in 
patients [76] and to test novel therapeutic agents [77]. Very recently, we have exploited this 
model to reveal the genetic complexity during GBM evolution by identifying the clones that 
possess the tumor-initiating capacity and are able to transfer the disease to immunosuppressed 
animals [26]. This study represents an initial step into the complexity of GBM temporal evolution 
that is further complicated by the influence of the tumor microenvironment and the application of 
radical treatments, i.e. chemotherapy and radiotherapy, which impact on the clonal architecture 
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of the tumor. There are many examples of drug resistance conferred by the emergence of 
subclones harbouring specific somatic mutations [78] that might be therapy-driven. 
This has been proven true for GBM that arises as a result of progression from a low-grade disease 
[19] but evidences in primary GBM are yet to come. 
 
The influence of epigenetics 
The most challenging type of heterogeneity occurs at the environmental level as this is 
extrinsically dynamic and multifactorial depending on different types of stromal cells, their 
interactions and different niches types (vascular, hypoxic, etc.) [79, 80]. The cellular 
microenvironment impacts the epigenetic status of a cell and the downstream epigenetic marks 
(methylation of cytosine nucleotides, histone protein modifications, chromatin remodeling 
complexes and noncoding RNA interference) will influence the transcriptional potential of the cell.  
Genomic hyper- and hypomethylation has been shown in many cancer types and is associated to 
tumor formation and progression. As DNA methylation occurs primarily at CG dinucleotides in 
mammals, many cancer studies have targeted CG-rich regions and analyzed their aberrant 
‘methylomes’ [81-83].  However, in recent years, non-CpG methylation has been found to regulate 
gene expression in embryonic stem cells and new research has focused on analysing the 
distribution and regulation of non-CpG methylation traits [84-86]. Genomic methylation patterns 
can vary among individual cells within the same tissue and are subject to dynamic changes during 
development [87, 88]. This epigenetic heterogeneity has also been described within tumors where 
only a subset of aberrant DNA methylation events are recurrently found across different tumor 
regions [89-91].  
In patients with GBM the oral alkylating agent temozolomide is the current standard of  
9 
 
care. This drug is more effective on tumors where there is epigenetic silencing of the O-6-
methylguanine-DNA methyltransferase (MGMT) gene encoding a methyltransferase that inhibits 
the cytotoxic effect of temozolomide. Two regions in the MGMT promoter have been recently 
identified as critical for transcriptional silencing and prediction of the response to alkylating agents 
[92]. Interestingly, hypermethylation of the MGMT promoter has been observed in all the 
subtypes of the Verhaak classification [34]. Recently, we have shown that MGMT methylation 
status seems to be quite homogeneous in different GBM tumor areas [8] and generally predicts 
response to temozolomide [5].  Notwithstanding, beneficial response to this drug has also been 
seen in MGMT-unmethylated tumors, which suggests that MGMT methylation changes over time 
[93] and is influenced by treatment [94] reflecting a temporal rather than spatial heterogeneous 
status.   
Several groups have described additional promoter hypermethylation in GBM, often influencing 
the expression of GBM tumor suppressor genes like PTEN and P53, as well as of regulatory genes 
involved in cell proliferation, invasion and cytokine signaling [95] . Also the expression of EGFRvIII 
has been shown to be epigenetically modulated through methylation and hystone acetylation [96]. 
Epigenomic profiling in GBM has revealed a distinct subgroup called glioma CpG island methylator 
phenotype (G-CIMP) [97] that is enriched for the proneural expression group. If analyzed in the 
context of the proneural subtype, the G-CIMP group is clinically characterized by longer survival 
and it is associated with IDH1 mutations [95, 97]. Interestingly, the MGMT promoter methylation 
is independent from the CpG island methylator phenotype. 
These findings were followed by a comprehensive epigenetic and biological classification of 
pediatric and adult GBM [98] that defined six GBM subtypes based on global DNA methylation 
patterns, IDH1 mutations and two mutations in aminoacids K27 and G34 of the histone variant 
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H3.3. Interestingly, the authors found that the anatomical localization of K27 and G34 mutant 
tumors was different (midline locations and embryonic regions of neocortex and striatum, 
respectively) and that these mutations occurred mainly in pediatric GBM [98]. The molecular 
mechanisms underlying the transcriptional signature of K27 mutant tumors were described in a 
subsequent study showing that the reduction of K27 trimethylation on histone H3 interferes with 
the enzymatic activity of histone methyltransferase EZH2. This causes alterations in H3K27me3 
occupancy at the transcription start site of promoters across the whole genome of K27 mutant 
tumors. As a result, a pronounced global DNA hypomethylation resetting drives the emergence of 
a K27 mutant-specific gene expression profile [99]. 
Epigenetic modulators are currently being targeted as druggable candidates in several cancers. 
Epigenetic therapy has been applied with reasonable success in hematologic malignancies using 
DNA methyltransferase (decitabine, 5-azacitidine) and histone deacetylase inhibitors (vorinostat, 
romidepsin). In contrast, relatively low efficacies have been achieved on solid tumors; this is likely 
due to their intrinsic heterogeneous nature which allows tumors to develop treatment resistance 
[100]. A fundamental characteristic of epigenetics is that the same genomic sequence can show 
alternative phenotypes by reprogramming gene expression. Thus, intratumor heterogeneity at the 
epigenetic level will be reflected into transcriptional variability within tumors which will affect its 
evolutionary potential and is of vital importance on future clinical decision making.  
 
Transcriptional analysis 
In a critical review of the pathology of cerebral gliomas in 1940, Scherer H.J. described that 
primary GBMs are constituted of at least two or more “distinct pathological entities” [101]. 
Transcriptional analysis in GBM has been extensively used with the aim to dissect the phenotypic 
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complexity well known already by pathologists almost 80 years ago. Following from gene 
expression profiling studies on oligodendrogiomas, astrocytomas and normal brain tissues, in 2005 
complementary DNA (cDNA) microarrays were used to analyze GBM specimens and identify genes 
associated with immune cells, hypoxia, extracellular matrix and cellular proliferation [102]. 
With the initial evidences of the CSC hypothesis applied to solid tumors, transcriptional 
profiling analysis has helped to identify pathways which might suggest normal stem cell parallels 
for cancer cells. In GBM, seminal studies have shown that tumor cells retain a stem cell signature 
[68, 103-107] and a lot of effort has been put in optimizing culture conditions that preserve the 
genetic and transcriptional profile of the original tumor. The ability of GBM tumor cells to mimic 
the functional properties of stem cells has been definitively described in a recent study by Suvà 
and colleagues [108] where transcriptional analysis has been fundamental to identify a set of 
critical neurodevelopmental transcription factors for GBM propagation (POU3F2 [BRN2], SOX2, 
SALL2, and OLIG2). 
In an initial study including all grades of astrocytic tumors, an artificial neural network 
algorithm was developed to define survival prognostic subtypes [109] (denoted ANGIO, INTER, and 
LOWER) that had a perfect correspondence with the histological grade of these tumors.  
More recently, several groups have focused on developing accurate molecular prognostic 
classification systems to specifically stratify GBM patients. To this aim, large cohort genome-wide 
profiling analyses [110-112] have attempted to use microarray gene expression data from 
hundreds of GBM samples. The largest analysis to date [110] identified four GBM subtypes: 
Proneural, Neural, Classical and Mesenchymal, each characterized by a distinct gene expression 
profile associated with prognosis and response to therapy. The Proneural subtype is characterized 
by aberrations in PDGFRA, p53 and IDH1 mutations. The Classical subtype presents all common 
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alterations of GBM (chromosome 7 amplification, chromosome 10 deletion, CDKN2A/B/p14ARF 
deletion and EGFR amplification). The Mesenchymal subtype shows high expression of CHI3L1 
(also known as YKL40) and MET and is characterized by NF1 deletion (that is sufficient to convert a 
Proneural GBM into a Mesenchymal  GBM both in vitro and in vivo [113]). The Neural subtype has 
the highest expression of neuronal markers and genes associated with axon and synaptic 
transmission and  it is typical of samples characterized mainly by normal tissue. Interestingly, the 
Neural subtype has been found to be characteristic of the margin area of GBM  which can be 
identified by using 5-ALA during surgical tumor debulking [68] (Piccirillo SGM et al., unpublished 
data). 
The clinical relevance of this classification relies on its association to survival and response to 
treatment that differs among subtypes: the Proneural subtype is associated with a trend toward 
longer survival but the better response to treatment is observed in the Classical subtype [110]. 
More recently, a different approach based on gene co-expression modules of key pathways, such 
as EGFR and PDGFR, has been explored to develop a clinically relevant classifier for both adult low-
grade and high-grade gliomas [114]. 
However, in the last years it became clear that given the extensive spatial genetic intratumor 
heterogeneity in GBM it is difficult to make sense of these data based on a single GBM sample per 
patient (Fig.1). Also, such classification does not segregate all the GBM key aberrations, in fact 
some are found in more than one subtype, in other words CDKN2A and CDKN2B, and are shared 
with low-grade gliomas [34] suggesting that they are essential for the stepwise malignant growth. 
More recently, transcriptome sequencing has been employed to reveal gene fusions in GBM [61] 
some of which occur in noncoding genes, resulting in the expression of noncoding RNAs that are  
not expressed in normal cells [115].  
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 In colorectal cancer, single-cell PCR gene expression analysis has been used to dissect the 
cellular composition of normal and cancer tissue [116]. In GBM, single-cell transcriptome analysis 
by RNA sequencing has revealed extensive intratumor heterogeneity and a “stem cell-
differentiation gradient” that is not fully recapitulated in in vitro models [27]. More importantly, 
single-cell analysis has confirmed that more than one sub-type coexists in the same tumor as 
previously reported [8] (Fig.1) and suggested that hybrid phenotypic states reminiscent of 
progenitor and differentiated cells are present in individual cells of the same GBM [27]. These data 
highlight the dynamics of cellular states in GBM that can have implications for developing new 
therapeutic approaches. An example of this dynamic regulation has been recently provided in a 
study about extrachromosomal EGFRvIII showing that GBM cells suppress the expression of 
EGFRvIII following treatment with tyrosine kinase inhibitors but is upregulated after drug removal 
[117]. 
In the last decade, thousands of computational methods and bioinformatics tools have 
been developed to analyze gene expression patterns initially derived from gene expression 
microarray measurements and more recently from RNA-sequencing data. Most of these 
bioinformatics tools have used empirical Bayes methods [118-120] or estimates of the mean and 
variance [121, 122] to analyze differential expression levels. These tools have been applied to 
quantify transcription levels among single biopsies from several cancer patients or between cancer 
patients and controls. 
New studies that consider the variability in intratumor expression levels include multiple samples 
from a single patient and/or multiple single cells from the same tumor. These studies aim at 
gaining a better understanding of regional and temporal transcriptional profiles within a tumor. 
However, new dependencies emerge from the measurements (mRNA expression levels for each 
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patient/tumor) taken on this type of experiments as neither the profiled genes nor the tissue 
samples/single cells are likely to be independent from a statistical point of view. These high-
dimensional, complex gene expression datasets lead to important statistical challenges. Firstly, the 
higher number of genes compared to the number of samples limits the application of multivariate 
tests. Secondly, the dependence among the tissue samples for each subject might restrict the use 
of practical approaches that rely on mixing univariate standard testing procedures such as ANOVA 
and multiple testing correction methods. An important factor for accurate identification of 
differentially expressed genes is the number of sample replicates (biological or technical) as most 
methods model the variability in gene expression measurements. However, in light of the 
extensive intratumor heterogeneity, biological replicates are not really adequate to study cancer 
datasets and running technical replicates of tumor samples is often difficult due to limiting starting 
material or elevated cost. Few new methods have been developed to overcome these limitations 
but an increasingly number of multisampling experiments are currently being processed. If not 
addressed, these issues will limit the potential of the multisampling and single-cell experiments 
and ultimately compromise the identification of potential prognostic/predictive signatures to 
develop better therapeutic approaches. Moreover, these problems would also affect the 
downstream functional analyses that investigate the pathways in which dis-regulated genes are 
involved. A recent publication by Touloumis and colleagues [123] describes a suitable method for 
both, studying the heterogeneous transcriptional levels within tumors and identifying those 
pathways or biological processes affected by genes that are heterogeneously expressed in 
different tumor regions. In this study, the authors found differential expression levels between 
three spatially separated regions of GBM tumors: the tumor mass, the SEZ and the tumor margin 
[5, 68]. Furthermore, when genes were classified into one of the Gene Ontology biological 
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processes they found marked functional heterogeneity as most of the analyzed groups harbor 
differentially expressed genes. 
Computational approaches that allow integration of transcriptomic, genomic and 
epigenomic data will be key to achieve a comprehensive understanding of intratumor 
heterogeneity. These methods will lead to new ‘heterogeneity signatures’ that will aid with clinical 
decision making to apply individualised treatments to cancer patients. 
 
Conclusion 
Intratumor heterogeneity highlights the complexity of tumor genomic landscape and may 
present major challenges to biomarker identification and overcoming treatment resistance. The 
existence of treatment resistant clones and the influence of microenvironment favour tumor 
relapse. In GBM initial insights into clonal distribution [5, 8, 26, 27] and cooperativity among EGFR 
variants [65, 124] have shed new light into the mechanisms underlying tumor heterogeneity. At 
trascriptional level, recent studies have shown a previously unrecognised heterogeneous profile in 
distinct region of the same GBMs as well as at single-cell level [5, 8, 27] (Fig. 1). These findings 
support the concept that a detailed molecular inter- and intra-patient analysis is needed to 
develop personalized therapies and eventually target regions of the same GBM with different 
therapeutic approaches.  
By comparing the SEZ and the tumor mass of the same patient, we have observed differential 
pattern of response to the standard treatment based on the alkylating agent temozolomide, 
cisplatin and cediranib [5]. Similar analyses on primary cells derived from different regions of the 
same GBM might inform therapeutic decision. 
Molecular tumor subtypes identified through transcriptional analysis have been proposed to be  
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clinically relevant and important for prognostic value, however these classifications did not take 
into account sample heterogeneity. Analysis of primary tumor cells and single-cell technologies 
might help refining the existing GBM subtype classification and improving patient stratification. 
Unfortunately, there is currently no approved therapy besides the Stupp protocol [45, 46], thus 
clinicians have no alternatives to offer after exhausting the traditional treatments (surgery, 
radiation, alkylating chemotherapy and eventually anti-angiogenetic therapy).  
Hence, performing exhaustive genetic, transcriptomic and epigenetic testing seem invaluable to 
provide insights into more personalized treatments and/or further therapeutic alternatives for 
GBM patients. Nevertheless, these molecular-based tests are certainly time consuming and the 
integration of the data is not trivial which makes the interpretation of the results quite complex. 
 
Future perspective 
 With the emergence of next-generation sequencing technologies, we have changed our 
understanding of tumor heterogeneity. These technologies have revealed an unexpected 
molecular complexity from bulk population to single-cell level and have challenged the way by 
which we think of cancer development and treatment.   
GBM is a remarkable example of a phenotypic and genetic heterogeneous tumor and despite the 
challenges associated with improving current treatments, there is hope that the integration of 
accurate data reflecting the genetic, transcriptional and epigenetic intratumor heterogeneity in 
addition to functional studies may lead to the definitive identification of tumor drivers and 
druggable therapeutic targets (Fig. 2).  
 
Executive summary 
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 Glioblastoma (GBM) is the most common and aggressive brain cancer in adults. 
 The prognosis of GBM remains dismal despite the current treatments based on surgical 
resection and combination of chemo- and radio-therapy.  
 Cancer stem cells have been isolated in GBM and their identification has helped define a 
model of phenotypic intratumor heterogeneity based on a hierarchical organization of cells 
with different tumorigenic potential. 
 Genetic and phenotypic intratumor heterogeneity has been described in GBM in seminal 
studies on RTK expression, phylogenetic reconstruction, high-throughput single-cell 
analysis and differential response to drug treatment. 
 Multiple-sampling and single-cell analysis have revealed different patterns of 
transcriptional profiling in the same GBM. 
 Many computational methods have been developed to interpret tumor transcriptional 
profiles yet, robust methods that are suitable for multi-sampling/single-cell experimental 
designs are much needed.  
 Bioinformatics tools that allow integration of transcriptomic, genomic and epigenetic data 
will be key to achieve a comprehensive understanding of intratumor heterogeneity that 
will lead to better classification of patients and aid to define novel therapeutic strategies 
important for clinical decision making. 
Conclusion 
 Transcriptional profiling needs to be further investigated in light of recent data of 
intratumor heterogeneity in GBM.  
 A comprehensive analysis of distinct tumor areas and single cells can shed new light on the  
molecular mechanisms sustaining tumor growth and develop more refined molecular  
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classifiers of GBM patients.  
Future perspective 
 Integration of genetic, phenotypic and transcriptional data with functional experiments can 
help design new molecular patient-specific therapeutic approaches. 
 
Figure legends  
Fig. 1. Transcriptional profiling of human GBM can be performed using: a single tumor sample, 
multiple samples taken from distinct tumor areas (5 samples from the tumor mass in the example 
shown consistently with Sottoriva&Spiteri and colleagues [8]) or at single-cell level (430 cells/GBM 
as described by Patel and colleagues [27]). The data generated by these 3 different approaches 
can be used to investigate intra-tumor heterogeneity at transcriptional level and potentially gain 
new insights into GBM biology and prognosis. By applying a previously published classifier, the 
multi-sampling scheme and single-cell analysis have revealed that multiple subtypes coexist in the 
same tumor with implications for patients stratification and response to standard therapy. 
Pron=Proneural, Mes= Mesenchymal, Cla= Classical. 
Fig. 2. Integration of spatial genetic, phenotypic, epigenetic and transcriptional intra-tumor 
heterogeneity with temporal analysis before and after treatment and functional in vitro and in vivo 
assays might lead to an in-depth molecular classification and to the development of personalized 
therapies aimed at improving patients survival. 
 
Financial disclosure 
The authors have no financial involvement with any organization or entity with a financial  
interest in or financial conflict with the subject matter or materials discussed in the manuscript. 
19 
 
No writing assistance was used in the production of this manuscript. 
 
References 
* = of interest 
** = of considerable interest 
1. Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer? 
Nat Rev Cancer 12(5), 323-334 (2012). 
2. Yates LR, Campbell PJ: Evolution of the cancer genome. Nat Rev Genet 13(11), 795-806 
(2012). 
3. Nik-Zainal S, Van Loo P, Wedge DC et al.: The life history of 21 breast cancers. Cell 149(5), 
994-1007 (2012). 
4. Campbell PJ, Pleasance ED, Stephens PJ et al.: Subclonal phylogenetic structures in cancer 
revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A 105(35), 13081-13086 (2008). 
5. Piccirillo SGM, Spiteri I, Sottoriva A et al.: Contributions to drug resistance in glioblastoma 
derived from malignant cells in the sub-ependymal zone. Cancer Res 75(1), 194-202 (2015). 
** Shows that a neurogenic region in the brain, the subependymal zone, is a reservoir of 
tumor cells in glioblastoma patients and emphasizes that these cells play a role into 
tumor growth dynamics and drug resistance. 
6. De Bruin EC, Mcgranahan N, Mitter R et al.: Spatial and temporal diversity in genomic 
instability processes defines lung cancer evolution. Science 346(6206), 251-256 (2014). 
7. Gerlinger M, Horswell S, Larkin J et al.: Genomic architecture and evolution of clear cell 
renal cell carcinomas defined by multiregion sequencing. Nat Genet 46(3), 225-233 (2014). 
8. Sottoriva A, Spiteri I, Piccirillo SGM et al.: Intratumor heterogeneity in human glioblastoma  
20 
 
reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110(10), 4009-4014 (2013). 
** Describes an integrated genomic analysis and phylogenetic reconstruction of 11 
glioblastoma using a multiple-sampling approach and shows that multiple subtypes are 
present in the same tumor. 
9. Gerlinger M, Quezada SA, Peggs KS et al.: Ultra-deep T cell receptor sequencing reveals the 
complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol 
231(4), 424-432 (2013). 
10. Szerlip NJ, Pedraza A, Chakravarty D et al.: Intratumoral heterogeneity of receptor tyrosine 
kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with 
distinct growth factor response. Proc Natl Acad Sci U S A 109(8), 3041-3046 (2012). 
11. Gerlinger M, Rowan AJ, Horswell S et al.: Intratumor heterogeneity and branched evolution 
revealed by multiregion sequencing. N Engl J Med 366(10), 883-892 (2012). 
12. Hernandez L, Wilkerson PM, Lambros MB et al.: Genomic and mutational profiling of ductal 
carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour 
genetic heterogeneity and clonal selection. J Pathol 227(1), 42-52 (2012). 
13. Snuderl M, Fazlollahi L, Le LP et al.: Mosaic amplification of multiple receptor tyrosine 
kinase genes in glioblastoma. Cancer Cell 20(6), 810-817 (2011). 
14. Campbell PJ, Yachida S, Mudie LJ et al.: The patterns and dynamics of genomic instability in 
metastatic pancreatic cancer. Nature 467(7319), 1109-1113 (2010). 
15. Yachida S, Jones S, Bozic I et al.: Distant metastasis occurs late during the genetic evolution 
of pancreatic cancer. Nature 467(7319), 1114-1117 (2010). 
16. Ding L, Ellis MJ, Li S et al.: Genome remodelling in a basal-like breast cancer metastasis and  
xenograft. Nature 464(7291), 999-1005 (2010). 
21 
 
17. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA: Genetic intra-tumour 
heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of 
tumours. J Pathol 211(3), 286-295 (2007). 
18. Bolli N, Avet-Loiseau H, Wedge DC et al.: Heterogeneity of genomic evolution and 
mutational profiles in multiple myeloma. Nat Commun 5, 2997 (2014). 
19. Johnson BE, Mazor T, Hong C et al.: Mutational analysis reveals the origin and therapy-
driven evolution of recurrent glioma. Science 343(6167), 189-193 (2014). 
20. Ding L, Ley TJ, Larson DE et al.: Clonal evolution in relapsed acute myeloid leukaemia 
revealed by whole-genome sequencing. Nature 481(7382), 506-510 (2012). 
21. Keats JJ, Chesi M, Egan JB et al.: Clonal competition with alternating dominance in multiple 
myeloma. Blood 120(5), 1067-1076 (2012). 
22. Cooke SL, Temple J, Macarthur S et al.: Intra-tumour genetic heterogeneity and poor 
chemoradiotherapy response in cervical cancer. Br J Cancer 104(2), 361-368 (2011). 
23. Shah SP, Morin RD, Khattra J et al.: Mutational evolution in a lobular breast tumour 
profiled at single nucleotide resolution. Nature 461(7265), 809-813 (2009). 
24. Mullighan CG, Phillips LA, Su X et al.: Genomic analysis of the clonal origins of relapsed 
acute lymphoblastic leukemia. Science 322(5906), 1377-1380 (2008). 
25. Shah NP, Nicoll JM, Nagar B et al.: Multiple BCR-ABL kinase domain mutations confer 
polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and 
blast crisis chronic myeloid leukemia. Cancer Cell 2(2), 117-125 (2002). 
26. Piccirillo SGM, Colman S, Potter NE et al.: Genetic and functional diversity of propagating 
cells in glioblastoma. Stem Cell Reports 4(1), 7-15 (2015). 
27. Patel AP, Tirosh I, Trombetta JJ et al.: Single-cell RNA-seq highlights intratumoral  
22 
 
heterogeneity in primary glioblastoma. Science 344(6190), 1396-1401 (2014). 
** Describes intratumor heterogeneity in glioblastoma at the highest possible resolution 
to date by using single-cell RNA sequencing to profile approximately 450 tumor cells 
from five human glioblastoma. 
28. Kreso A, O'brien CA, Van Galen P et al.: Variable clonal repopulation dynamics influence 
chemotherapy response in colorectal cancer. Science 339(6119), 543-548 (2013). 
29. Navin N, Kendall J, Troge J et al.: Tumour evolution inferred by single-cell sequencing. 
Nature 472(7341), 90-94 (2011). 
30. Anderson K, Lutz C, Van Delft FW et al.: Genetic variegation of clonal architecture and 
propagating cells in leukaemia. Nature 469(7330), 356-361 (2011). 
31. Notta F, Mullighan CG, Wang JC et al.: Evolution of human BCR-ABL1 lymphoblastic 
leukaemia-initiating cells. Nature 469(7330), 362-367 (2011). 
32. Bourzac K: Biology: Three known unknowns. Nature 509(7502), S69-71 (2014). 
33. Junttila MR, De Sauvage FJ: Influence of tumour micro-environment heterogeneity on 
therapeutic response. Nature 501(7467), 346-354 (2013). 
34. Goodenberger ML, Jenkins RB: Genetics of adult glioma. Cancer Genet 205(12), 613-621 
(2012). 
35. Collins VP: Mechanisms of disease: genetic predictors of response to treatment in brain 
tumors. Nat Clin Pract Oncol 4(6), 362-374 (2007). 
36. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J 
Pathol 170(5), 1445-1453 (2007). 
37. Parsons DW, Jones S, Zhang X et al.: An integrated genomic analysis of human glioblastoma  
multiforme. Science 321(5897), 1807-1812 (2008). 
23 
 
38. Yan H, Parsons DW, Jin G et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8), 
765-773 (2009). 
39. Schlegel J, Merdes A, Stumm G et al.: Amplification of the epidermal-growth-factor-
receptor gene correlates with different growth behaviour in human glioblastoma. Int J 
Cancer 56(1), 72-77 (1994). 
40. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J: Amplification of epidermal growth factor 
receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51(1), 
84-90 (1992). 
41. Jaros E, Perry RH, Adam L et al.: Prognostic implications of p53 protein, epidermal growth 
factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66(2), 373-385 (1992). 
42. Vogt N, Lefevre SH, Apiou F et al.: Molecular structure of double-minute chromosomes 
bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc 
Natl Acad Sci U S A 101(31), 11368-11373 (2004). 
43. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor 
suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 
83(6), 993-1000 (1995). 
44. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing 
specific inhibition of cyclin D/CDK4. Nature 366(6456), 704-707 (1993). 
45. Stupp R, Mason WP, Van Den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med 352(10), 987-996 (2005). 
46. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-
analysis of individual patient data from 12 randomised trials. Lancet 359(9311), 1011-1018  
(2002). 
24 
 
47. Kleihues P, Sobin LH: World Health Organization classification of tumors. Cancer 88(12), 
2887 (2000). 
48. Nabors LB: Targeted molecular therapy for malignant gliomas. Curr Treat Options Oncol 
5(6), 519-526 (2004). 
49. Magee JA, Piskounova E, Morrison SJ: Cancer stem cells: impact, heterogeneity, and 
uncertainty. Cancer Cell 21(3), 283-296 (2012). 
50. Visvader JE: Cells of origin in cancer. Nature 469(7330), 314-322 (2011). 
51. Wikstrand CJ, Bigner SH, Bigner DD: Demonstration of complex antigenic heterogeneity in a 
human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer 
Res 43(7), 3327-3334 (1983). 
52. Shapiro JR, Yung WK, Shapiro WR: Isolation, karyotype, and clonal growth of 
heterogeneous subpopulations of human malignant gliomas. Cancer Res 41(6), 2349-2359 
(1981). 
53. Jung V, Romeike BF, Henn W et al.: Evidence of focal genetic microheterogeneity in 
glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J 
Neuropathol Exp Neurol 58(9), 993-999 (1999). 
54. Harada K, Nishizaki T, Ozaki S, Kubota H, Ito H, Sasaki K: Intratumoral cytogenetic 
heterogeneity detected by comparative genomic hybridization and laser scanning 
cytometry in human gliomas. Cancer Res 58(20), 4694-4700 (1998). 
55. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the 
p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S 
transition control gene abnormalities. Cancer Res 60(2), 417-424 (2000). 
56. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP: Infrequent methylation of  
25 
 
CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in 
primary astrocytic tumours. Br J Cancer 75(1), 2-8 (1997). 
57. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or 
CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54(24), 6321-6324 
(1994). 
58. Ueki K, Ono Y, Henson JW, Efird JT, Von Deimling A, Louis DN: CDKN2/p16 or RB alterations 
occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56(1), 150-
153 (1996). 
59. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of 
the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the 
retinoblastoma gene. Oncogene 13(5), 1065-1072 (1996). 
60. Brennan CW, Verhaak RG, Mckenna A et al.: The somatic genomic landscape of 
glioblastoma. Cell 155(2), 462-477 (2013). 
** Presents the most recent TCGA data comprising 578 glioblastoma patients from 17 
centers. These data are based on integration of exome-seq, RNA-seq, copy-number, DNA 
methylation, protein, mRNA and miRNA profiles. 
61. Frattini V, Trifonov V, Chan JM et al.: The integrated landscape of driver genomic 
alterations in glioblastoma. Nat Genet 45(10), 1141-1149 (2013). 
62. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines 
human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008). 
63. Inda MM, Bonavia R, Mukasa A et al.: Tumor heterogeneity is an active process maintained 
by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24(16), 1731-1745  
(2010). 
26 
 
64. Heimberger AB, Suki D, Yang D, Shi W, Aldape K: The natural history of EGFR and EGFRvIII 
in glioblastoma patients. J Transl Med 3, 38 (2005). 
65. Fan QW, Cheng CK, Gustafson WC et al.: EGFR phosphorylates tumor-derived EGFRvIII 
driving STAT3/5 and progression in glioblastoma. Cancer Cell 24(4), 438-449 (2013). 
* Shows the cell-intrinsic interaction between two key drivers of glioblastoma growth, 
EGFR wild type and its variant vIII, and highlights the molecular mechanism downstream 
of their oncogenic cooperativity. 
66. Li L, Puliyappadamba VT, Chakraborty S et al.: EGFR wild type antagonizes EGFRvIII-
mediated activation of Met in glioblastoma. Oncogene, (2013). 
67. Francis JM, Zhang CZ, Maire CL et al.: EGFR variant heterogeneity in glioblastoma resolved 
through single-nucleus sequencing. Cancer Discov 4(8), 956-971 (2014). 
68. Piccirillo SGM, Dietz S, Madhu B et al.: Fluorescence-guided surgical sampling of 
glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the 
tumour mass and margin. Br J Cancer 107(3), 462-468 (2012). 
** Highlights the use of 5-ALA technology to interrogate distinct tumor regions of 
glioblastoma. 
69. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-
guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised 
controlled multicentre phase III trial. The lancet oncology 7(5), 392-401 (2006). 
70. Chen J, Mckay RM, Parada LF: Malignant glioma: lessons from genomics, mouse models, 
and stem cells. Cell 149(1), 36-47 (2012). 
71. Chen J, Li Y, Yu TS et al.: A restricted cell population propagates glioblastoma growth after  
chemotherapy. Nature 488(7412), 522-526 (2012). 
27 
 
72. Alcantara Llaguno S, Chen J, Kwon CH et al.: Malignant astrocytomas originate from neural 
stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15(1), 45-
56 (2009). 
73. Wang Y, Yang J, Zheng H et al.: Expression of mutant p53 proteins implicates a lineage 
relationship between neural stem cells and malignant astrocytic glioma in a murine model. 
Cancer Cell 15(6), 514-526 (2009). 
74. Zheng H, Ying H, Yan H et al.: p53 and Pten control neural and glioma stem/progenitor cell 
renewal and differentiation. Nature 455(7216), 1129-1133 (2008). 
75. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN: Combined activation of Ras 
and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25(1), 55-
57 (2000). 
76. Joo KM, Kim J, Jin J et al.: Patient-specific orthotopic glioblastoma xenograft models 
recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep 3(1), 
260-273 (2013). 
77. Piccirillo SG, Reynolds BA, Zanetti N et al.: Bone morphogenetic proteins inhibit the 
tumorigenic potential of human brain tumour-initiating cells. Nature 444(7120), 761-765 
(2006). 
78. Fisher R, Pusztai L, Swanton C: Cancer heterogeneity: implications for targeted 
therapeutics. Br J Cancer 108(3), 479-485 (2013). 
79. Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the 
tumor microenvironment. Cancer Cell 21(3), 309-322 (2012). 
80. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 144(5), 646-674  
(2011). 
28 
 
81. Kostareli E, Holzinger D, Bogatyrova O et al.: HPV-related methylation signature predicts 
survival in oropharyngeal squamous cell carcinomas. J Clin Invest 123(6), 2488-2501 (2013). 
82. Szyf M: DNA methylation signatures for breast cancer classification and prognosis. Genome 
Med 4(3), 26 (2012). 
83. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP: DNA methylation biomarkers 
for lung cancer. Tumour Biol 33(2), 287-296 (2012). 
84. Guo JU, Su Y, Shin JH et al.: Distribution, recognition and regulation of non-CpG 
methylation in the adult mammalian brain. Nat Neurosci 17(2), 215-222 (2014). 
85. Truong M, Yang B, Wagner J, Desotelle J, Jarrard DF: Analysis of promoter non-CG 
methylation in prostate cancer. Epigenomics 5(1), 65-71 (2013). 
86. Ziller MJ, Muller F, Liao J et al.: Genomic distribution and inter-sample variation of non-CpG 
methylation across human cell types. PLoS Genet 7(12), e1002389 (2011). 
87. Tanasijevic B, Dai B, Ezashi T, Livingston K, Roberts RM, Rasmussen TP: Progressive 
accumulation of epigenetic heterogeneity during human ES cell culture. Epigenetics 4(5), 
330-338 (2009). 
88. Stoger R, Kajimura TM, Brown WT, Laird CD: Epigenetic variation illustrated by DNA 
methylation patterns of the fragile-X gene FMR1. Hum Mol Genet 6(11), 1791-1801 (1997). 
89. Easwaran H, Tsai HC, Baylin SB: Cancer epigenetics: tumor heterogeneity, plasticity of 
stem-like states, and drug resistance. Mol Cell 54(5), 716-727 (2014). 
90. Smallwood SA, Lee HJ, Angermueller C et al.: Single-cell genome-wide bisulfite sequencing 
for assessing epigenetic heterogeneity. Nat Methods 11(8), 817-820 (2014). 
91. Brocks D, Assenov Y, Minner S et al.: Intratumor DNA methylation heterogeneity reflects  
clonal evolution in aggressive prostate cancer. Cell Rep 8(3), 798-806 (2014). 
29 
 
92. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K: A distinct 
region of the MGMT CpG island critical for transcriptional regulation is preferentially 
methylated in glioblastoma cells and xenografts. Acta Neuropathol 121(5), 651-661 (2011). 
93. Brandes AA, Franceschi E, Tosoni A et al.: O(6)-methylguanine DNA-methyltransferase 
methylation status can change between first surgery for newly diagnosed glioblastoma and 
second surgery for recurrence: clinical implications. Neuro Oncol 12(3), 283-288 (2010). 
94. Parkinson JF, Wheeler HR, Clarkson A et al.: Variation of O(6)-methylguanine-DNA 
methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J 
Neurooncol 87(1), 71-78 (2008). 
95. Sturm D, Bender S, Jones DT et al.: Paediatric and adult glioblastoma: multiform 
(epi)genomic culprits emerge. Nat Rev Cancer 14(2), 92-107 (2014). 
* Highlights the genetic and epigenetic hallmarks of pediatric and adult glioblastoma. 
96. Del Vecchio CA, Giacomini CP, Vogel H et al.: EGFRvIII gene rearrangement is an early event 
in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic 
mechanisms. Oncogene 32(21), 2670-2681 (2013). 
97. Noushmehr H, Weisenberger DJ, Diefes K et al.: Identification of a CpG island methylator 
phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5), 510-522 (2010). 
98. Sturm D, Witt H, Hovestadt V et al.: Hotspot mutations in H3F3A and IDH1 define distinct 
epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4), 425-437 (2012). 
99. Bender S, Tang Y, Lindroth AM et al.: Reduced H3K27me3 and DNA hypomethylation are 
major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 
24(5), 660-672 (2013). 
100. Ho AS, Turcan S, Chan TA: Epigenetic therapy: use of agents targeting deacetylation and  
30 
 
methylation in cancer management. Onco Targets Ther 6, 223-232 (2013). 
101. Scherer HJ: A Critical Review: The Pathology of Cerebral Gliomas. J Neurol Psychiatry 3(2), 
147-177 (1940). 
102. Liang Y, Diehn M, Watson N et al.: Gene expression profiling reveals molecularly and 
clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102(16), 
5814-5819 (2005). 
103. Sandberg CJ, Altschuler G, Jeong J et al.: Comparison of glioma stem cells to neural stem 
cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint 
associated with clinical outcome. Exp Cell Res 319(14), 2230-2243 (2013). 
104. Engstrom PG, Tommei D, Stricker SH, Ender C, Pollard SM, Bertone P: Digital transcriptome 
profiling of normal and glioblastoma-derived neural stem cells identifies genes associated 
with patient survival. Genome Med 4(10), 76 (2012). 
105. Pollard SM, Yoshikawa K, Clarke ID et al.: Glioma stem cell lines expanded in adherent 
culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. 
Cell Stem Cell 4(6), 568-580 (2009). 
106. Lee J, Kotliarova S, Kotliarov Y et al.: Tumor stem cells derived from glioblastomas cultured 
in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than 
do serum-cultured cell lines. Cancer Cell 9(5), 391-403 (2006). 
107. Galli R, Binda E, Orfanelli U et al.: Isolation and characterization of tumorigenic, stem-like 
neural precursors from human glioblastoma. Cancer Res 64(19), 7011-7021 (2004). 
108. Suvà ML, Rheinbay E, Gillespie SM et al.: Reconstructing and reprogramming the tumor-
propagating potential of glioblastoma stem-like cells. Cell 157(3), 580-594 (2014). 
109. Petalidis LP, Oulas A, Backlund M et al.: Improved grading and survival prediction of human  
31 
 
astrocytic brain tumors by artificial neural network analysis of gene expression microarray 
data. Mol Cancer Ther 7(5), 1013-1024 (2008). 
110. Verhaak RG, Hoadley KA, Purdom E et al.: Integrated genomic analysis identifies clinically 
relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, 
and NF1. Cancer Cell 17(1), 98-110 (2010). 
** Describes a gene-expression based classification of glioblastoma into four clinically 
relevant subtypes and their functional annotation using somatic mutations and DNA 
copy number data of the TCGA cohort. 
111. Phillips HS, Kharbanda S, Chen R et al.: Molecular subclasses of high-grade glioma predict 
prognosis, delineate a pattern of disease progression, and resemble stages in 
neurogenesis. Cancer Cell 9(3), 157-173 (2006). 
112. Freije WA, Castro-Vargas FE, Fang Z et al.: Gene expression profiling of gliomas strongly 
predicts survival. Cancer Res 64(18), 6503-6510 (2004). 
113. Ozawa T, Riester M, Cheng YK et al.: Most human non-GCIMP glioblastoma subtypes evolve 
from a common proneural-like precursor glioma. Cancer Cell 26(2), 288-300 (2014). 
114. Sun Y, Zhang W, Chen D et al.: A glioma classification scheme based on coexpression 
modules of EGFR and PDGFRA. Proc Natl Acad Sci U S A 111(9), 3538-3543 (2014). 
115. Shah N, Lankerovich M, Lee H, Yoon JG, Schroeder B, Foltz G: Exploration of the gene 
fusion landscape of glioblastoma using transcriptome sequencing and copy number data. 
BMC Genomics 14, 818 (2013). 
116. Dalerba P, Kalisky T, Sahoo D et al.: Single-cell dissection of transcriptional heterogeneity in 
human colon tumors. Nat Biotechnol 29(12), 1120-1127 (2011). 
117. Nathanson DA, Gini B, Mottahedeh J et al.: Targeted therapy resistance mediated by  
32 
 
dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343(6166), 72-76 
(2014). 
118. Law CW, Chen Y, Shi W, Smyth GK: voom: Precision weights unlock linear model analysis 
tools for RNA-seq read counts. Genome Biol 15(2), R29 (2014). 
119. Robinson MD, Mccarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics 26(1), 139-140 (2010). 
120. Hardcastle TJ, Kelly KA: baySeq: empirical Bayesian methods for identifying differential 
expression in sequence count data. BMC Bioinformatics 11, 422 (2010). 
121. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L: Differential analysis of 
gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 31(1), 46-53 (2013). 
122. Anders S, Huber W: Differential expression analysis for sequence count data. Genome Biol 
11(10), R106 (2010). 
123. Touloumis A, S. T, J.C. M: Testing the Mean Matrix in High-Dimensional Transposable Data. 
Biometrics arXiv:1404.7683 (2015). 
124. Bonavia R, Inda MM, Cavenee WK, Furnari FB: Heterogeneity maintenance in glioblastoma: 
a social network. Cancer Res 71(12), 4055-4060 (2011). 
 
 
 
